EUVIMEDEUVIMED entdecken
Crossref

Atrial Fibrillation, Anticoagulants, and CRC Outcomes: A Nationwide 20-Year Study

Arnar S Agustsson iD, Sigurdis Haraldsdottir, Helgi Birgisson, Sigrun H Lund, Arnar B Ingason, Johann P Hreinsson, Einar S Bjornsson

Thrombosis and Haemostasis · 23.02.2026

DOI: 10.1055/a-2810-0347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 23.02.2026. Verfasst von Arnar S Agustsson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Iceland, Reykjavik, Iceland. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Eimskipasjodur at the University of Iceland, Scientific grant of Landspitali.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a leading cause of cancer-related death and presents most often with occult or overt gastrointestinal bleeding (GIB). Oral anticoagulation (OAC) use has been hypothesized to increase the rate of GIB events and potentially cause early detection of CRC. This study aimed to investigate whether prior use of OAC could decrease overall or cancer-specific mortality in patients with CRC. All patients with CRC in Iceland from 2000 to 2019 were identified from the Icelandic Cancer Registry. Through a detailed review of medical records, clinical data were obtained. Comorbidity was assessed using the Charlson comorbidity index. Inverse probability weighting was used to balance the study groups. Of 2,563 patients, 173 were taking OACs due to atrial fibrillation and were diagnosed with CRC. OAC users were predominantly older males with a higher comorbidity index. While staging was not significantly different, tumor size and lymph node metastases were different. After weighting, OAC users had a similar overall mortality (HR = 1.08; 95% CI, 0.91–1.28, p = 0.37), but lower CRC-specific mortality (HR = 0.75; 95% CI, 0.57–1.00, p = 0.046), specifically in the first 5 years. Cardiovascular mortality was significantly higher in OAC users. Patients on OACs due to atrial fibrillation had lower CRC-specific mortality, suggesting that OAC use could be associated with survival benefits through early detection of CRC. However, these results should be interpreted carefully due to substantial competing cardiovascular mortality.

Autor:innen und Institutionen

  • Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Department of Medical Oncology, Landspitali University Hospital of Iceland, Reykjavik, Iceland.
  • The Icelandic Cancer Registry, Reykjavik, Iceland.
  • Faculty of Physical Science, University of Iceland, Reykjavik, Iceland.
  • Department of Surgery, University of Vermont Larner College of Medicine, Burlington, Vermont, United States.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

ORCID-Profile: Arnar S Agustsson

Förderung

  • Eimskipasjodur at the University of Iceland
  • Scientific grant of Landspitali

Zitieren

APA

Agustsson, A. S., Haraldsdottir, S., Birgisson, H., Lund, S. H., Ingason, A. B., Hreinsson, J. P., & Bjornsson, E. S. (2026). Atrial Fibrillation, Anticoagulants, and CRC Outcomes: A Nationwide 20-Year Study. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2810-0347

Vancouver

Agustsson AS, Haraldsdottir S, Birgisson H, Lund SH, Ingason AB, Hreinsson JP, et al. Atrial Fibrillation, Anticoagulants, and CRC Outcomes: A Nationwide 20-Year Study. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2810-0347

BibTeX
@article{Agustsson2026,
  author = {Agustsson, Arnar S and Haraldsdottir, Sigurdis and Birgisson, Helgi and Lund, Sigrun H and Ingason, Arnar B and Hreinsson, Johann P and Bjornsson, Einar S},
  title = {Atrial Fibrillation, Anticoagulants, and CRC Outcomes: A Nationwide 20-Year Study},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1055/a-2810-0347}
}
Kostenlos starten →